EC[ON]OMY

Why Kazakhstan Needs Stronger Pharma Regulations Now

In recent years the pharmaceutical industry has come under growing scrutiny for anti-competitive practices – especially in the United States, where drug prices are far higher than in Europe. One of the main tools to bring prices down is generic competition. But brand-name pharma companies have found ways to sidestep the rules.

Researchers uncovered a common and calculated practice: branded drugmakers make deals with potential generic challengers, paying them to delay their market entry. These “pay-for-delay” agreements mean the patent holder essentially pays its competitor to stay off the market – keeping prices high and competition out.

A study of 64 public patent settlements in the U.S. from 2014 to 2023 found signs of collusion in 17 of them. Stock markets responded immediately: brand-name companies saw their share prices jump by an average of 3.5% after such deals were announced – a sign that investors expected big profits from extended monopolies.

The cost to consumers? An estimated $3.1–3.2 billion per year from just those 17 deals. With other undisclosed agreements factored in, the total annual damage may reach $12 billion.

Kazakhstan is at a critical juncture in building a competitive pharmaceutical market. Generic and biosimilar medicines – cheaper alternatives to brand-name drugs – are key to controlling public health costs and improving access to treatment.

But this growth phase brings both opportunity and risk. As the U.S. experience shows, it’s exactly when competition starts rising that backroom deals emerge to delay or block access.

Kazakhstan has already begun steps to support generics: creating a national formulary, speeding up drug registration, and promoting local production. However, without strong oversight of the patent system and market behavior, these efforts risk being undermined by “pay-for-delay” style arrangements behind closed doors.

The takeaway: If Kazakhstan doesn’t put safeguards in place now, powerful pharmaceutical players may import the same tactics that cost U.S. consumers billions.

To prevent Kazakhstan’s pharma sector from sliding into a closed system of hidden monopolies, a proactive strategy is needed. Here are five key policy steps:

1. Create a Mandatory Registry of Patent Settlements.

Any patent settlement between a brand and a generic company should be reported to the regulator and entered into a semi-public database. This registry should list key details: date, parties, generic entry date, exclusivity terms, AG (authorized generic) refusals, and more.

2. Monitor Drug Prices Before and After Generic Entry.

If prices don’t drop after a patent expires, that’s a red flag. The Health Ministry, insurance fund, or an independent watchdog should track this regularly and act before distortions become systemic.

3. Crack Down on “Secondary” Patents.

Many companies file new patents not on the active ingredient, but on minor changes – like taste, packaging, or dosage form. Known as “evergreening,” these tactics delay competition. Kazakhstan needs stricter rules for approving such patents, including proof of real innovation and clinical value, plus an appeal process for competitors.

4. Develop a Fast-Response Mechanism to Suspect Deals.

The competition authority should be able to launch investigations without waiting for complaints. Signs like unexplained generic delays, AG withdrawals, or stock price spikes should trigger a fast-track review: request documents, assess market impact, and impose temporary controls if needed.

5. Use the Stock Market as an Early Warning System.

If pharma stocks traded on local exchanges like KASE surge after patent news, it could signal a hidden agreement. In the future, Kazakhstan could even create a “generic transparency index” that tracks market and regulatory indicators.

The key lesson from the U.S. case is simple: the pharma world doesn’t run on fair competition ideals – it runs on incentives. If collusion is cheaper than fighting in court, companies will choose collusion. That’s not cynicism – it’s economic logic.

Big pharma firms serve shareholders. If delaying a generic launch by one year earns them $500 million, and paying a competitor $100 million keeps them away – the choice is obvious. Especially when the legal risks are low.

So the role of regulators is not to “educate the market,” but to make unfair practices too risky and unprofitable. How? By exposing schemes, imposing high penalties, and closing legal loopholes.

If Kazakhstan wants a truly competitive pharma market, now is the time to act. Delay will only open the door to imported monopolistic tactics. The price will be paid by ordinary people – through higher drug prices, weaker competition, and reduced access to care.

But there’s a real chance today to build a system where fair competition isn’t a dream – it’s the default. That’s not just smart regulation. It’s a strategic move for public health and national resilience.

    

Guldariya Manakpaeva, Executive Director of the “PharmMedIndustry Kazakhstan” Association, specifically for http://www.economyKZ.org

Scroll to Top